Evidence map›Paper›PMID 30233859›Full record

ArticleJournal of thoracic disease2018

Frequency of actionable alterations in epidermal growth factor receptor

Elisa Chiadini, Matteo Canale, Angelo Delmonte, Claudio Dazzi, Claudia Casanova, Laura Capelli, Marita Mariotti, Maximilian Papi, Alessandro Gamboni, Maurizio Puccetti and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of thoracic disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Elisa ChiadiniBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Matteo CanaleBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Angelo DelmonteDepartment of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Claudio DazziMedical Oncology Unit, S. Maria delle Croci Hospital, Ravenna, Italy.
Claudia CasanovaMedical Oncology Unit, S. Maria delle Croci Hospital, Ravenna, Italy.
Laura CapelliBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Marita MariottiDepartment of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Maximilian PapiOncology and Oncohematology Unit, Infermi Hospital, Rimini, Italy.
Alessandro GamboniMedical Oncology Unit, Infermi Hospital, Faenza, Italy.
Maurizio PuccettiPathology Unit, S. Maria delle Croci Hospital, Ravenna, Italy.
Sara BravacciniBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Alessandra DubiniPathology Unit, Morgagni-Pierantoni Hospital, Forlì, Italy.
Daniele CalistriBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Lucio CrinòDepartment of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Paola UliviBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITOspedale "Santa Maria delle Croci" di Ravenna · ITOspedale G.B. Morgagni - L.Pierantoni · ITOspedale Infermi di Rimini · ITOspedale per gli Infermi · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMolecular diagnostics for non-small cell lung cancer (NSCLC) has become the standard of care for personalized treatment. Epidermal growth factor receptor (

methodsOne thousand consecutive NSCLC patients with

resultsThree hundred and forty-eight (34.8%), 31 (3.1%), 39 (4.4%), 14 (1.8%), 6 (0.7%), 16 (1.8%), 5 (0.6%) and 9 (0.9%) patients showed an alteration in

conclusionsAbout 50% of our patients had a potentially targetable alteration, confirming the usefulness of a multiparametric approach for routine molecular diagnostics aimed at identifying potential therapeutic targets.

Indexed as

epidermal growth factor receptor (EGFR)Formalin-fixed paraffin-embedded samples (FFPE samples)multitarget analysisNon-small cell lung cancer (NSCLC)targeted therapy

Identifiers

PMID30233859
PMCPMC6129926
OpenAlexW2885847016

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.